Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern / Steglatro / Steglujan / Segluromet
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The diabetes Type-2 drugs Invokana, Farxiga, and Jardiance, as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet have been associated with these serious side effects:
- Fournier’s Gangrene (Necrotizing Fasciitis of the Perineum)
- Leg Amputations
- Foot Amputations
- Toe(s) Amputations
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed the medical conditions listed above.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
At the recent American Diabetes Association (ADA) Scientific Sessions there were reportedly questions raised about whether there is an increased risk of Fournier’s gangrene when using Farxiga as well as other SGLT2 inhibitor diabetes drugs such as Invokana and Jardiance.
From this July 18, 2019 article published online by Medscape, “Fournier Gangrene and Genitourinary Infections With SGLT2 Inhibitors: ADA 2019 Update”, we get these details:
To read more of this article, click below:
At the recent American Diabetes Association (ADA) Scientific Sessions, more details were presented on the adverse events in DECLARE-TIMI 58, the first trial of SGLT2 inhibitors completed after the FDA warnings on FG. The investigators planned to collect serious adverse events and any adverse events leading to drug discontinuation, but went back and did an in-depth check for necrotizing fascitis in light of the concerns.
They identified six cases of FG among study participants; five occurred in the placebo group (Table). Lawrence A. Leiter, MD, University of Toronto, Ontario, Canada, said in a press conference at ADA that on the basis of the DECLARE-TIMI 58 data, SGLT2 inhibitors do not seem to increase the risk and that FG is a diabetes-associated complication.
This Medscape article included a response to that contention by Susan Bersoff-Matcha, MD, of the FDA’s Center for Drug Evaluation and Research, who said the DECLARE-TIMI 58 data are still under review by the FDA. She went on to comment:
At this time, our opinion regarding the association between SGLT2 inhibitor use and FG has not changed. We, however, note that the DECLARE-TIMI 58 study only evaluated patients using [Farxiga (dapagliflozin)] and may not be reflective for the SGLT2 inhibitor drug class [as a whole].
We will continue to watch for evidence that Fournier’s gangrene is Farxiga side effect as well as Invokana, Jardiance, and other SGLT2 inhibitor diabetes drugs — or that it is not a drug side effect of these medicines.[Read article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Cases Of Fournier Gangrene Associated With Diabetes Drugs Invokana, Jardiance, And Farxiga
- Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?
- Farxiga And Jardiance Have Two-Time Increased Risk For Amputations
- Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
- Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
- Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
- Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
- Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
- Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
- New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
- Invokana – Amputations: No Explanation Yet As Regards “How” And “Why”
- “Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
- FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
- Invokana Gets “Black-Box Warning” For Risk Of Leg And Foot Amputations
- Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
- Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
- Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
- New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
List of SGLT2 Inhibitors
|Drug Name||Active Ingredient(s)||Drug Manufacturer||FDA Approval Date|
|Invokamet||canagliflozin / metformin||Janssen Pharmaceuticals||2014|
|Invokamet XR||canagliflozin / metformin extended-release||Janssen Pharmaceuticals||2016|
|Xigduo XR||dapagliflozin / metformin extended-release||AstraZeneca Pharmaceuticals||2014|
|Qtern||dapagliflozin / saxagliptin||AstraZeneca Pharmaceuticals||2017|
|Jardiance||empagliflozin||Boehringer Ingelheim Pharmaceuticals||2014|
|Glyxambi||empagliflozin / linagliptin||Boehringer Ingelheim Pharmaceuticals||2015|
|Synjardy||empagliflozin / metformin hydrochloride||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2015|
|Synjardy XR||empagliflozin / metformin hydrochloride extended-release||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2016|
|Steglatro||ertugliflozin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Steglujan||ertugliflozin / sitagliptin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Segluromet||ertugliflozin / metformin hydrochloride||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
All content by attorney Tom Lamb